STERIS (NYSE:STE) Given New $270.00 Price Target at UBS Group

STERIS (NYSE:STE) had its target price decreased by UBS Group from $275.00 to $270.00 in a research note released on Friday morning,Benzinga reports. UBS Group currently has a buy rating on the medical equipment provider’s stock.

A number of other equities analysts also recently commented on STE. Weiss Ratings downgraded STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research report on Wednesday, May 27th. KeyCorp dropped their target price on STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a report on Wednesday, May 13th. Piper Sandler reaffirmed an “overweight” rating and issued a $275.00 target price (up from $270.00) on shares of STERIS in a research note on Friday. Finally, Wall Street Zen lowered STERIS from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $271.33.

STERIS Stock Up 2.6%

STE stock opened at $237.70 on Friday. The company has a market cap of $23.17 billion, a price-to-earnings ratio of 29.06 and a beta of 0.91. The company has a current ratio of 1.91, a quick ratio of 1.54 and a debt-to-equity ratio of 0.23. STERIS has a 12 month low of $195.14 and a 12 month high of $269.44. The firm has a 50-day moving average of $214.86 and a two-hundred day moving average of $225.48.

STERIS (NYSE:STE) last issued its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.49 by $0.10. The business had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.49 billion. STERIS had a return on equity of 14.34% and a net margin of 13.34%.The business’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.34 EPS. STERIS has set its FY 2027 guidance at 11.000-11.300 EPS. As a group, analysts forecast that STERIS will post 11.17 earnings per share for the current fiscal year.

STERIS Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 25th. Investors of record on Friday, September 4th will be issued a $0.69 dividend. The ex-dividend date is Friday, September 4th. This represents a $2.76 annualized dividend and a dividend yield of 1.2%. This is a boost from STERIS’s previous quarterly dividend of $0.63. STERIS’s dividend payout ratio (DPR) is presently 30.81%.

Insider Buying and Selling

In related news, VP John Adam Zangerle sold 1,419 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $209.28, for a total transaction of $296,968.32. Following the completion of the transaction, the vice president directly owned 35,259 shares in the company, valued at $7,379,003.52. This trade represents a 3.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel A. Carestio sold 3,054 shares of STERIS stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $214.64, for a total value of $655,510.56. Following the completion of the transaction, the chief executive officer directly owned 65,021 shares of the company’s stock, valued at approximately $13,956,107.44. This represents a 4.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 7,328 shares of company stock valued at $1,554,051. Corporate insiders own 1.12% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Jones Financial Companies Lllp boosted its position in STERIS by 46.1% in the 1st quarter. Jones Financial Companies Lllp now owns 1,106 shares of the medical equipment provider’s stock valued at $251,000 after buying an additional 349 shares during the period. Goldman Sachs Group Inc. increased its position in shares of STERIS by 32.3% during the first quarter. Goldman Sachs Group Inc. now owns 242,732 shares of the medical equipment provider’s stock worth $55,015,000 after acquiring an additional 59,264 shares during the period. Empowered Funds LLC increased its position in shares of STERIS by 16.1% during the first quarter. Empowered Funds LLC now owns 2,303 shares of the medical equipment provider’s stock worth $522,000 after acquiring an additional 319 shares during the period. Woodline Partners LP raised its stake in shares of STERIS by 40.0% in the first quarter. Woodline Partners LP now owns 8,300 shares of the medical equipment provider’s stock valued at $1,881,000 after acquiring an additional 2,372 shares in the last quarter. Finally, Jane Street Group LLC raised its stake in shares of STERIS by 38.9% in the first quarter. Jane Street Group LLC now owns 20,716 shares of the medical equipment provider’s stock valued at $4,695,000 after acquiring an additional 5,803 shares in the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

Key Headlines Impacting STERIS

Here are the key news stories impacting STERIS this week:

• Positive Sentiment: Piper Sandler raised its price target to $275 from $270 while reaffirming an “overweight” rating. The revised target implies roughly 16% potential upside from the referenced share price, signaling continued confidence in STERIS’s earnings growth and medical-equipment demand. Benzinga analyst rating report
• Positive Sentiment: Fiscal first-quarter adjusted EPS came in at $2.59, ahead of the approximately $2.49 consensus estimate, while revenue rose 7.3% year over year to $1.49 billion. Growth was broad-based: Healthcare revenue increased 8%, Applied Sterilization Technologies rose 6% and Life Sciences advanced 9%. STERIS fiscal 2027 first-quarter results
• Positive Sentiment: STERIS plans to invest approximately $600 million in a North Carolina manufacturing hub expected to create about 335 jobs. The project should expand production capacity and support the company’s formulated-chemistries business over the longer term. STERIS North Carolina manufacturing investment
• Neutral Sentiment: Fiscal 2027 guidance was maintained broadly in line with expectations. Adjusted EPS is projected at approximately $11.00–$11.30 and revenue at about $6.4 billion, consistent with expected 7%–8% revenue growth. The company increased capital-expenditure guidance to roughly $450 million and expects free cash flow of about $800 million.
• Negative Sentiment: Revenue was described as modestly below some estimates despite the earnings beat, and operating cash flow declined year over year. STERIS also expects $55 million–$70 million in pretax restructuring charges tied to the North Carolina center, creating near-term cost and execution risks. STERIS earnings analysis

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.